Live News Reader

Some of the articles presented on this website are accessed through RSS feeds from third-party sources that are not necessarily part of the Histiocytosis Association. While we try to select appropriate feeds to prevent objectionable content from being displayed, the presence of any article does not indicate endorsement or recommendation by the Histiocytosis Association.

If you know of a histio-related article that isn't shown here, please send the article to outreach@histio.org.

Erdheim-Chester disease - Google News
This RSS feed URL is deprecated
This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news
Monday, August 20, 2018 10:55:43 PM

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer - FDA.gov

Medscape

FDA approves first treatment for certain patients with Erdheim-Chester Disease, a rare blood cancer
FDA.gov
The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood. Zelboraf is indicated to treat patients whose ...
First-Ever FDA Approval for Erdheim-Chester Disease
First Tx for Erdheim-Chester Disease, a Rare Blood Cancer
FDA Approves Zelboraf (Vemurafenib) for Erdheim-Chester Disease with BRAF V600 Mutation
 - -

Monday, November 06, 2017 11:39:27 AM

CNS Abnormalities Common in Erdheim-Chester Disease - Neurology Advisor

Neurology Advisor

CNS Abnormalities Common in Erdheim-Chester Disease
Neurology Advisor
Patients with Erdheim-Chester disease (ECD) are at risk for a variety of central nervous system (CNS) abnormalities, and brain and spine magnetic resonance imaging (MRI) may be necessary to determine the extent of disease and its possible prognosis, ...


Friday, February 23, 2018 8:36:41 AM

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease - Cancer Network

Cancer Network

FDA Approves Vemurafenib for Treating Erdheim-Chester Disease
Cancer Network
The US Food and Drug Administration (FDA) has expanded the approval of vemurafenib (Zelboraf) to include the treatment of a rare, slow-growing blood cancer, Erdheim–Chester disease, for adult BRAF V600–positive patients. This marks the first approval ...


Thursday, November 09, 2017 3:29:33 PM

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis - Cancer Therapy Advisor

Cancer Therapy Advisor

Vemurafenib Effective in BRAF-mutated Erdheim-Chester Disease and Langerhans Cell Histiocytosis
Cancer Therapy Advisor
Vemurafenib confers a durable and clinically beneficial effect among patients with BRAF-mutant Erdheim-Chester disease (ECD) or Langerhans cell histiocytosis (LCH), according to a study published in JAMA Oncology.1. Although patients with ECD or LCH ...


Thursday, November 30, 2017 1:39:52 PM

On Rare Disease Day, experts say 'Don't give up' - KING5.com

KING5.com

On Rare Disease Day, experts say 'Don't give up'
KING5.com
“Stand up. Talk about it. Get involved, donate, volunteer, don't give up,” said Kathy Brewer, president of the Erdheim-Chester Disease Global Alliance. “Sometimes it can seem overwhelming, especially when those who are meant to help us, like a doctor ...


Wednesday, February 28, 2018 11:12:54 PM

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation - Rare Disease Report

Erdheim-Chester Disease Treatment Gets FDA Priority Review and Breakthrough Therapy Designation
Rare Disease Report
The U.S. Food and Drug Administration (FDA) has accepted Genentech's supplemental New Drug Application (sNDA) and granted Priority Review for Zelboraf (vemurafenib), a therapy for patients with Erdheim-Chester disease (ECD) with a BRAF V600 ...


Monday, August 07, 2017 10:29:49 AM

Genes associated with Erdheim-Chester disease also linked to cancer - Science Daily

Genes associated with Erdheim-Chester disease also linked to cancer
Science Daily
National Human Genome Research Institute (NHGRI) researchers have identified new genes associated with the Erdheim-Chester disease (ECD) and some possible new therapies. Findings on this ultra-rare disease, found in approximately 600 people in the ...


Monday, April 03, 2017 12:40:33 PM

High Response Rate in Histiocytic Disease With MEK Inhibition - OncLive

OncLive

High Response Rate in Histiocytic Disease With MEK Inhibition
OncLive
“Single-agent cobimetinib has robust activity in Erdheim-Chester disease (ECD), Langerhans cell histiocytosis (LCH), and Rosai-Dorfman disease (RDD), regardless of BRAF mutational status,” said Eli Diamond, MD, a neuro-oncologist at Memorial Sloan ...


Wednesday, January 03, 2018 3:00:33 PM

Martin's Lofaro trying to beat rare disease - Jackson Sun

Jackson Sun

Martin's Lofaro trying to beat rare disease
Jackson Sun
MARTIN – “You're sick. There's no cure. You can't beat this.” Those were the three statements that resonated with Joe Lofaro in October of 2015 when he was diagnosed with Erdheim Chester's Disease (ECD). Lofaro said his response took a few seconds to ...


Tuesday, February 27, 2018 5:44:20 PM

Share with Others

© Histiocytosis Association, Inc.
332 North Broadway, Pitman, New Jersey  08071 USA
Phone: +1 856-589-6606 | Fax: +1 856-589-6614
| info@histio.org
Privacy | DisclaimerState Fundraising Notices 
Tax ID: 22-2827069 | Contact Us 
Follow Me on Pinterest   


¿No Habla Inglés? Si usted puede escribirme sus preguntas y preocupaciones a la dirección de correo electrónico: outreach@histio.org. Nosotros podremos responderle tan pronto nos sea possible. Gracias!